These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 39237515)

  • 41. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment.
    Levine AB; Nobre L; Das A; Milos S; Bianchi V; Johnson M; Fernandez NR; Stengs L; Ryall S; Ku M; Rana M; Laxer B; Sheth J; Sbergio SG; Fedoráková I; Ramaswamy V; Bennett J; Siddaway R; Tabori U; Hawkins C
    Nat Commun; 2024 Jul; 15(1):5790. PubMed ID: 38987542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
    Chen H; Hu W; He H; Yang Y; Wen G; Lv X
    Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
    Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
    Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
    Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S
    Elife; 2020 Sep; 9():. PubMed ID: 32902381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of H3 K27M-mutant gliomas in adults.
    Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
    Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma.
    Körner M; Spohn M; Schüller U; Bockmayr M
    Oncoimmunology; 2024; 13(1):2386789. PubMed ID: 39135890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
    Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
    J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells.
    Huang TY; Piunti A; Qi J; Morgan M; Bartom E; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2020 Dec; 8(1):219. PubMed ID: 33287886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
    Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
    Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic prediction and immune checkpoint profiling in glioma patients through neddylation-associated features.
    Qi J; Li L; Gao B; Dai K; Shen K; Wu X; Li H; Yu Z; Wang Z; Wang Z
    Gene; 2024 Dec; 930():148835. PubMed ID: 39127414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
    Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
    Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. H3 G34-mutant high-grade glioma.
    Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
    Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.